Semaglutide at $120 per month.
A source-dated explanation of Luma Health’s month-to-month compounded semaglutide offer, what is included, and what a clinician still must determine.
Editorial review pending: Hamilton Johnson
Current source check: September 20, 2026. A prescription, product selection, and fulfillment remain subject to individualized clinical and pharmacy review.
What the $120 monthly price means
The current price on Luma’s transparent-pricing page is $120 for month-to-month injectable compounded semaglutide. It is billed monthly with no minimum term. This is the amount presented for that month-to-month option; it is not an annual-prepayment equivalent or a brand-name medication price. Review the current pricing page before enrolling.
Included on the published plan
Luma’s pricing page states that plans include a provider consultation, prescription, medication, and shipping. This treatment page also describes medication and provider visits as included. Portal messaging is available 24/7; phone support is available 9 AM–11 PM EST. Portal messaging does not promise an immediate clinical response.
What still depends on review
Completing an intake or paying for a consultation does not guarantee a prescription. A licensed clinician reviews the individual’s information and determines whether treatment is medically appropriate. The dispensing pharmacy handles fulfillment after a prescription is issued. Availability can vary by state, treatment, provider, pharmacy, and other requirements.
Who is named in the published program
Luma identifies clinical consultations and prescriptions as reviewed through Wasef Health, P.A. Its pricing page identifies VialsRX as a Texas State Board-licensed 503A pharmacy (License #35264). Those operational disclosures do not make a compounded preparation FDA-approved or establish that it is interchangeable with a brand-name finished drug.
Monthly billing or a clearly labeled prepaid commitment
A lower monthly equivalent is not the same thing as a lower amount due today. The totals below are the current first-party terms checked on September 20, 2026.
| Option | Amount due and billing | How to read the number |
|---|---|---|
| Month to month | $120 per month, billed monthly | No minimum term is stated. This is the canonical $120 offer, rather than a prepaid equivalent. |
| 3-month plan | $240 total if prescribed | The page displays an $80-per-month equivalent. The multi-month amount is paid in full if prescribed. |
| 6-month plan | $470 total if prescribed | The page displays a $78-per-month equivalent. This is a prepaid six-month commitment, not a $78 monthly bill. |
| 12-month plan | Ask the provider for current pricing | No public 12-month semaglutide dollar amount is stated here, so this page does not infer one. |
Before you choose: The published program says multi-month plans are paid in full if prescribed. The month-to-month plan is billed monthly with no minimum term. At checkout, review the exact charge, whether a purchase recurs, the renewal amount and frequency, and the applicable cancellation terms. Luma’s billing terms say all sales are final and no refunds are provided. Current price details · billing terms · refund and cancellation policy.
Compounded semaglutide is not an FDA-approved finished drug
Luma’s offer concerns compounded semaglutide. It is not Wegovy, Ozempic, or another FDA-approved brand-name finished product. FDA says compounded drugs do not undergo FDA review for safety, effectiveness, or quality before marketing. FDA recommends an FDA-approved drug when it is available and appropriate for the patient; a compounded drug may be considered when a patient’s medical needs cannot be met by an FDA-approved drug or when the approved drug is not commercially available. FDA’s current GLP-1 information[1] explains why a common ingredient name does not establish that two finished products are the same, interchangeable, or supported by the same evidence.
For regulatory context, FDA explains that a 503A compounder must meet applicable conditions, including compounding based on a valid prescription for an individual patient. Federal restrictions on compounding drugs that are essentially copies of commercially available products also matter. A pharmacy label or a reference to 503A status is therefore not a blanket promise that any compounded product is available or appropriate in every circumstance. Read FDA’s compounding and shortages guidance[2].
Wegovy is the FDA-approved semaglutide product for chronic weight management for appropriate patients. Ozempic is a different branded semaglutide product with its own FDA-approved indications. FDA-approved labeling, not a compounded-product marketing page, controls a brand product’s indication, contraindications, warnings, formulation, and dose instructions. Neither a brand trial nor a brand label validates a compounded finished product.
Cost is only one part of the decision
Medication choice and eligibility are individualized clinical questions. The information below is educational, not a personal treatment recommendation.
A clinician evaluates the whole picture
- Medical history, current medicines, and possible interactions
- Potential benefits, risks, cost, and product category
- Pregnancy or pregnancy-planning considerations
- Whether treatment fits alongside nutrition and physical activity
Safety questions to discuss before treatment
- Personal or family history of medullary thyroid cancer or MEN 2
- History of pancreatitis, severe stomach problems, gallbladder disease, kidney disease, or diabetic retinopathy
- Other medicines, including insulin or medicines that can lower blood sugar
- Nausea, vomiting, diarrhea, abdominal pain, vision changes, or other concerning symptoms
Questions to answer before paying
A price is easier to evaluate when its product category, billing interval, and operating terms are written down together.
Name the product
Confirm whether the offer is an FDA-approved finished drug or a compounded preparation. Do not treat those categories as interchangeable.
Calculate today’s total
For a package, record the full amount due today rather than only the displayed monthly equivalent. Check every included and additional charge at checkout.
Read the future-billing terms
Review whether the purchase renews, the billing frequency, and the cancellation timing that applies before completing an order.
Confirm fulfillment and support
Standard shipping is free. Luma estimates 2–3 business days, but delivery is not guaranteed and can vary. Use 24/7 portal messaging or phone support from 9 AM–11 PM EST for order questions; clinical questions should go to the care team.
Shipping is limited to locations where treatment can legally be provided, and it may vary by state, provider, pharmacy, and product. See the shipping policy for the current estimate, limits, and delay information.
Cost and product
questions.
This page is an informational pricing explanation, not medical advice or a guarantee of prescription, coverage, fulfillment, delivery, or results.
As checked on September 20, 2026, Luma’s transparent-pricing page lists injectable compounded semaglutide at $120 per month for the month-to-month plan, billed monthly with no minimum term. This is a published price, not a guarantee that a clinician will prescribe or that treatment is available to a particular person.
No. The displayed $80 and $78 figures are per-month equivalents. The current published commitments are $240 total for three months and $470 total for six months, paid in full if prescribed. Ask a provider for current 12-month pricing; this page does not state an undisclosed total.
Luma’s pricing page says plans include provider consultation, prescription, medication, and shipping. The semaglutide page also states medication, provider visits, and 24/7 portal messaging. Checkout remains the place to confirm the full order amount and applicable terms before payment.
No. Luma describes its product as compounded semaglutide. Compounded drugs are not FDA-approved and FDA does not review them for safety, effectiveness, or quality before marketing. Wegovy and Ozempic are distinct FDA-approved finished products with their own labeling and indications.
No. A licensed clinician determines whether treatment is medically appropriate. Results, coverage, availability, fulfillment, and individual experience vary. Discuss your history, other medicines, pregnancy plans, possible side effects, and questions about product choice with a licensed clinician.
Commercial disclosure: Luma Health offers compounded semaglutide and may benefit if you enroll. FDA-approved brand-name medication may be preferable for some patients.
Review the full terms
before you start.
Compare the month-to-month price with prepaid totals, product category, and the current checkout disclosures. A licensed clinician makes the prescribing decision.
Sources checked September 20, 2026
- U.S. Food and Drug Administration, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”. Content current September 1, 2026; accessed September 20, 2026.
- U.S. Food and Drug Administration, “Compounding when Drugs are on FDA’s Drug Shortages List”. Content current August 8, 2025; accessed September 20, 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases, “Prescription Medications to Treat Overweight & Obesity”. Accessed September 20, 2026.
- MedlinePlus, “Semaglutide Injection”. Last revised May 15, 2026; accessed September 20, 2026.
- Luma Health, “Transparent Pricing”. Current price, plan total, included-service, pharmacy, and provider disclosures checked September 20, 2026.
- Luma Health, “Shipping Policy”. Shipping cost, estimate, availability, and delay qualifications checked September 20, 2026.
- Luma Health, “Billing Terms & Conditions” and “Auto-Refill & Cancellation Policy”. Payment, renewal, cancellation, and all-sales-final terms checked September 20, 2026.